Timeline Of Russian Sputnik V Covid-19 Vaccine, Approved For Emergency Use In India
by Bhaswati Guha Majumder - Apr 13, 2021 03:55 PM
Russian Covid-19 vaccine Sputnik V
Snapshot
A quick look at the journey of Russian Covid-19 vaccine Sputnik V, from its early days till its entry in India.
Russia s Covid-19 vaccine is the worldâs first to be registered based on the human adenoviral vector-based platform.
Now, India has become the sixtieth country to approve the two-dose Sputnik V vaccine after the Drugs Controller General of India (DCGI) gave the green signal.
Here is the journey of Sputnik V and its entry into India.
CARE BBB- rating assigned to proposed NCD issue of Wockhardt Limited
Posted On: 2021-04-06 05:13:59 (Time Zone: Arizona, USA)
CARE Ratings Limited (CARE Ratings) has assigned Wockhardt Limited s proposed Non-Convertible Debenture issue aggregating to Rs. 200 crore a rating of CARE BBB-; Stable (Triple B Minus; Outlook: Stable) .
The rating assigned to proposed non-convertible debenture issue factors in improvement in company s liquidity position post closure of sale of select divisions of domestic formulations business to Dr. Reddy s Laboratories Limited (DRL). The company received Rs. Rs.1483 crore upfront and Rs.67 crore were deposited in Escrow account out of which Rs.54 crore have been credited to WL in Q1FY21 which has improved company s liquidity position over medium term. The rating continues to derive strength from established track record of company in global pharmaceutical industry as well as experienced and resourceful promoters. WL s rating also derive strength
Foreign investors should note that PLI schemes are fast becoming the preferred vehicle for India's incentives to boost local manufacturing capacity creation.
Laxmi Organic Industries Limited IPO to open on Monday, March 15, 2021
Posted On: 2021-03-09 08:59:47 (Time Zone: Arizona, USA)
Laxmi Organic Industries Limited ( Company or Laxmi Organic ), will open the Bid/Offer period in relation to its initial public offering of Equity Shares (the Offer / IPO ) on Monday, March 15, 2021 and close on Wednesday, March 17, 2021. The price band for the Offer has been decided at Rs. 129 - Rs. 130 per Equity Share. The Company may, in consultation with the book running lead managers (the BRLMs ), consider participation by anchor investors ( Anchor Investors ) which shall be one Working Day prior to the Bid/Offer Opening Date, i.e. Friday, March 12, 2021.
Vivimed Labs Limited receives 2 product approvals from Uzbekistan
Posted On: 2021-03-08 04:42:48 (Time Zone: Arizona, USA)
Vivimed Labs Limited ( Vivimed or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad
PRODUCT: Bilastin tablets( Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine Hi receptor antagonist)
USES: It is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).
PRODUCT: Orzole combi
USES: Ofloxacin + Ornidazole is used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.